CLEVELAND, March 7, 2017 /PRNewswire/ -- Today, PathoBiome announces the launch of the first and only probiotic engineered to address the significant role fungi plays in digestive health. Considered the "next generation" performance probiotic, BIOHM combines beneficial fungi strains, beneficial bacteria strains and a powerful enzyme developed to break down digestive plaque and maintain total balance in the digestive system.
BIOHM's patent-pending formulation was guided by the cutting edge research of Dr. Mahmoud Ghannoum, Ph.D., MBA, FIDSA, the scientist credited with naming the mycobiome (the body's fungal community) and who spent his entire academic career studying medically important fungi.
Dr. Ghannoum's research – recently presented to the National Institute of Health (NIH) – shows evidence that fungi (not bacteria) is responsible for aggravating the severity of digestive issues. His research also indicates that bacteria and fungi work together to form digestive plaque, similar to dental plaque. Digestive plaque forms a shield around bad fungi and bacteria, allowing the damaging organisms to create imbalance in the digestive system.
"It's not an overstatement when we say this is a 'game changer' in consumer healthcare, digestive wellness, and the probiotic category as a whole," said Afif Ghannoum, CEO of PathoBiome, the makers of BIOHM Probiotics. "Ignoring fungi is like ignoring the 800 lb. gorilla in the digestive system. When you only maintain the good bacteria in the gut, fungus is allowed to flourish causing digestive imbalance. For the first time, consumers will be able to balance the total microbiome of bacteria and fungi in the digestive system with BIOHM."
Available online and retailing at $49.99 for a six week supply, BIOHM comes in a daily capsule form within a heat resistant jar, which protects BIOHM's 30 billion live cultures of good bacteria and good fungi.
BIOHM is ideal for any consumer who wants to maintain a healthy gut microbiome, promote optimal digestive health, and support his/her immunity. For the estimated 15% of Americans who suffer from digestive challenges, BIOHM is engineered to relieve occasional digestive issues such as, upset stomach, diarrhea and bowel irritation. BIOHM's strains have also been proven to break down digestive plaque while supporting immune health as well as overall digestive health.
For more information go to www.BIOHMHealth.com
ABOUT DR. MAHMOUD GHANNOUM
Mahmoud Ghannoum, Ph.D., MBA, FIDSA, joined Case Western Reserve University and University Hospitals Cleveland Medical Center in 1996 from his prior position at the UCLA School of Medicine. As the acclaimed scientist who named the mycobiome (the body's fungal community), Dr. Ghannoum has spent his entire academic career studying medically important fungi and the major causes of fungal infections.
He published more than 400 peer-reviewed articles and has been cited 16,000 times by other scientists, with coverage in CBS News, Forbes, Scientific American, USA Today, ABC News. Dr. Ghannoum lectures to the National Institute of Health (NIH) and has been a NIH-funded researcher since 1993 with $25 million in funding to date.
BLAZE PR / Matt Kovacs
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/first-probiotic-to-address-the-critical-role-of-fungi-in-digestive-health-hits-market-300419148.html